JP2005532840A - 局所的治療のための酵素表面を有する医療器具 - Google Patents
局所的治療のための酵素表面を有する医療器具 Download PDFInfo
- Publication number
- JP2005532840A JP2005532840A JP2003561659A JP2003561659A JP2005532840A JP 2005532840 A JP2005532840 A JP 2005532840A JP 2003561659 A JP2003561659 A JP 2003561659A JP 2003561659 A JP2003561659 A JP 2003561659A JP 2005532840 A JP2005532840 A JP 2005532840A
- Authority
- JP
- Japan
- Prior art keywords
- enzyme
- medical device
- enzymatically active
- active medical
- enzymes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 87
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 87
- 238000011282 treatment Methods 0.000 title claims description 22
- 230000000699 topical effect Effects 0.000 title description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 16
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims abstract description 15
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims abstract description 11
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims abstract description 11
- 150000001840 cholesterol esters Chemical class 0.000 claims abstract description 9
- 239000004475 Arginine Substances 0.000 claims abstract description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 8
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims abstract description 7
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims abstract description 7
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960004544 cortisone Drugs 0.000 claims abstract description 7
- 108091005804 Peptidases Proteins 0.000 claims abstract description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 5
- 235000006408 oxalic acid Nutrition 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 36
- 230000002792 vascular Effects 0.000 claims description 12
- 239000011159 matrix material Substances 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 210000004204 blood vessel Anatomy 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 230000000593 degrading effect Effects 0.000 claims description 6
- 210000003709 heart valve Anatomy 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 3
- 208000024720 Fabry Disease Diseases 0.000 claims description 3
- 208000015872 Gaucher disease Diseases 0.000 claims description 3
- 201000008450 Intracranial aneurysm Diseases 0.000 claims description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 3
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 3
- 230000009830 antibody antigen interaction Effects 0.000 claims description 3
- 229940106189 ceramide Drugs 0.000 claims description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 3
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 claims description 3
- 230000037451 immune surveillance Effects 0.000 claims description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 3
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 108010089254 Cholesterol oxidase Proteins 0.000 claims description 2
- 108090000371 Esterases Proteins 0.000 claims description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 2
- 108010055297 Sterol Esterase Proteins 0.000 claims description 2
- 102000000019 Sterol Esterase Human genes 0.000 claims description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 2
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 2
- 239000011247 coating layer Substances 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 230000007246 mechanism Effects 0.000 claims description 2
- 210000003625 skull Anatomy 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 108010063734 Oxalate oxidase Proteins 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 21
- -1 spheres Substances 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 239000000758 substrate Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 229920001400 block copolymer Polymers 0.000 description 7
- 229920002635 polyurethane Polymers 0.000 description 6
- 239000004814 polyurethane Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 239000004952 Polyamide Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920002647 polyamide Polymers 0.000 description 5
- 229920000098 polyolefin Polymers 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000005038 ethylene vinyl acetate Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 229920002302 Nylon 6,6 Polymers 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004989 dicarbonyl group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000012968 metallocene catalyst Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920006216 polyvinyl aromatic Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical class COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 229920002614 Polyether block amide Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical group 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229920006218 cellulose propionate Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 229920006213 ethylene-alphaolefin copolymer Polymers 0.000 description 1
- 229920005680 ethylene-methyl methacrylate copolymer Polymers 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920005995 polystyrene-polyisobutylene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920006215 polyvinyl ketone Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 229920006214 polyvinylidene halide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (32)
- 医療器具本体と、
プロテアーゼ酵素類、グリコシダーゼ酵素類、コレステロールエステルを分解する酵素類、ヒドロコルチゾンをコルチゾンに変換する酵素類、シュウ酸を分解する酵素類、アルギニンからNOを生成する酵素類からなるグループから選択され、上記医療器具本体に酵素的に活性な表面を提供するよう上記医療器具本体の表面又は表面近傍に配設された酵素とを備える酵素的に活性な医療器具。 - 上記酵素は、プロテアーゼ酵素であることを特徴とする請求項1記載の酵素的に活性な医療器具。
- 上記酵素は、コレステロールエステルを分解する酵素であることを特徴とする請求項1記載の酵素的に活性な医療器具。
- 上記酵素は、コレステロールエステラーゼ及びコレステロールオキシダーゼから選択されることを特徴とする請求項3記載の酵素的に活性な医療器具。
- 上記酵素は、ヒドロコルチゾンをコルチゾンに変換する酵素であることを特徴とする請求項1記載の酵素的に活性な医療器具。
- 上記酵素は、ヒドロコルチゾンエステラーゼ酵素であることを特徴とする請求項5記載の酵素的に活性な医療器具。
- 上記酵素は、グリコシダーゼ酵素であることを特徴とする請求項5記載の酵素的に活性な医療器具。
- 上記酵素は、α−ガラクトシダーゼ酵素であることを特徴とする請求項7記載の酵素的に活性な医療器具。
- 上記酵素は、β−ガラクトシダーゼ酵素であることを特徴とする請求項7記載の酵素的に活性な医療器具。
- 上記酵素は、β−グルコシダーゼ酵素であることを特徴とする請求項7記載の酵素的に活性な医療器具。
- 上記酵素は、アルギニンからNOを生成する酵素であることを特徴とする請求項1記載の酵素的に活性な医療器具。
- 上記酵素は、一酸化窒素合成酵素であることを特徴とする請求項11記載の酵素的に活性な医療器具。
- 上記酵素は、上記医療器具上に形成された生体適合性及び生体安定性を有するマトリックスコーティング内に配設されることを特徴とする請求項1記載の酵素的に活性な医療器具。
- 上記酵素は、上記医療器具の表面に付着されることを特徴とする請求項1記載の酵素的に活性な医療器具。
- 上記酵素は、上記医療器具の表面に共有結合されることを特徴とする請求項14記載の酵素的に活性な医療器具。
- 上記酵素は、イオン交換力によって上記医療器具の上記表面に付着されることを特徴とする請求項14記載の酵素的に活性な医療器具。
- 上記酵素は、抗体抗原相互作用によって上記医療器具の上記表面に付着されることを特徴とする請求項14記載の酵素的に活性な医療器具。
- 上記酵素は、核酸のハイブリダイゼーションによって上記医療器具の上記表面に付着されることを特徴とする請求項14記載の酵素的に活性な医療器具。
- 上記酵素は、上記医療器具において、表面コーティングに付着されることを特徴とする請求項14記載の酵素的に活性な医療器具。
- 上記酵素上に形成され、該酵素を免疫監視機構から隠す無酵素コーティング層(enzyme-free coating layer)を更に備える請求項1記載の酵素的に活性な医療器具。
- 上記医療器具本体は、血管用医療器具であることを特徴とする請求項1記載の酵素的に活性な医療器具。
- 上記医療器具本体は、カテーテル、ガイドワイヤ、バルーン、フィルタ、ステント、ステントグラフト、脳動脈瘤フィラ、血管グラフト、心臓弁、包帯及び充填剤から選択されることを特徴とする請求項1記載の酵素的に活性な医療器具。
- 請求項1記載の酵素的に活性な医療器具を準備するステップと、
上記医療器具を患者に適用するステップとを有する治療方法。 - 上記医療器具本体は、血管用医療器具であることを特徴とする請求項23記載の治療方法。
- 上記医療器具本体は、カテーテル、ガイドワイヤ、バルーン、フィルタ、ステント、ステントグラフト、脳動脈瘤フィラ、血管グラフト、心臓弁、包帯及び充填剤から選択されることを特徴とする請求項23記載の治療方法。
- 上記酵素は、ヒドロコルチゾンをコルチゾンに変換する酵素であり、上記医療器具は、炎症部位に適用されることを特徴とする請求項23記載の治療方法。
- 上記酵素は、アルギニンからNOを生成する酵素であり、上記医療器具は、血管内の部位に適用されて再狭窄を防ぐことを特徴とする請求項23記載の治療方法。
- 上記酵素は、コレステロールエステルに作用する酵素であり、上記医療器具は、血管内の動脈硬化プラークに隣接して配置され、上記動脈硬化プラーク内のコレステロールエステル堆積物を分解することを特徴とする請求項23記載の治療方法。
- 上記酵素は、ファブリー病の治療においてセラミドトリヘキソシドを分解するのに有効なグリコシダーゼ酵素であり、上記医療器具は、血液に接触する器具であることを特徴とする請求項23記載の治療方法。
- 上記酵素は、ゴーシェ病の治療においてグルコセレブロシドを分解するのに有効なグリコシダーゼ酵素であり、上記医療器具は、血液に接触する器具であることを特徴とする請求項23記載の治療方法。
- 上記酵素は、テイ−サックス病の治療においてガングリオシドGM2を分解するのに有効なグリコシダーゼ酵素であり、上記医療器具は頭蓋内に移植されることを特徴とする請求項23記載の治療方法。
- 上記酵素はシュウ酸酸化酵素であり上記医療器具は尿道カテーテルであることを特徴とする請求項23記載の治療方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/057,596 US7407668B2 (en) | 2002-01-24 | 2002-01-24 | Medical articles having enzymatic surfaces for localized therapy |
PCT/US2003/002020 WO2003061718A2 (en) | 2002-01-24 | 2003-01-23 | Medical articles having enzymatic surfaces for localized therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005532840A true JP2005532840A (ja) | 2005-11-04 |
JP2005532840A5 JP2005532840A5 (ja) | 2011-04-21 |
Family
ID=22011582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003561659A Ceased JP2005532840A (ja) | 2002-01-24 | 2003-01-23 | 局所的治療のための酵素表面を有する医療器具 |
Country Status (6)
Country | Link |
---|---|
US (2) | US7407668B2 (ja) |
EP (1) | EP1478412A2 (ja) |
JP (1) | JP2005532840A (ja) |
AU (1) | AU2003210630A1 (ja) |
CA (1) | CA2478773A1 (ja) |
WO (1) | WO2003061718A2 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8486389B2 (en) * | 1997-05-23 | 2013-07-16 | Oxthera, Inc. | Compositions and methods for treating or preventing oxalate-related disease |
US9114199B2 (en) * | 2003-07-31 | 2015-08-25 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent |
US7320675B2 (en) | 2003-08-21 | 2008-01-22 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure |
WO2005039664A2 (en) * | 2003-10-14 | 2005-05-06 | Cube Medical A/S | Medical device with electrospun nanofibers |
CA2448995A1 (en) * | 2003-11-12 | 2005-05-12 | James Keenan | Device and method for attracting diseased cells and foreign substances |
US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
WO2005105171A1 (en) * | 2004-04-29 | 2005-11-10 | Cube Medical A/S | A balloon for use in angioplasty with an outer layer of nanofibers |
WO2005110469A2 (en) * | 2004-05-07 | 2005-11-24 | Oxthera, Inc. | Methods and compositions for reducing oxalate concentrations |
US7764995B2 (en) * | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7729761B2 (en) * | 2004-07-14 | 2010-06-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlled gene or protein delivery |
US7621906B2 (en) * | 2004-08-25 | 2009-11-24 | Cardiac Pacemakers, Inc. | Method and apparatus to deliver drug and pacing therapy for treatment of cardiac disorders |
JP5047190B2 (ja) * | 2005-12-14 | 2012-10-10 | オクセラ インコーポレイテッド | シュウ酸塩関連疾患を治療または予防するための医薬組成物および方法 |
EP1976553B1 (en) * | 2005-12-16 | 2011-02-23 | OxThera, Inc., | Compositions and methods for oxalate reduction |
WO2010014541A2 (en) * | 2008-07-28 | 2010-02-04 | Alnara Pharmaceuticals, Inc. | Compositions and methods for treatment of hypercholesterolemia |
BRPI0900858A2 (pt) * | 2009-04-23 | 2011-05-03 | Clinica De Andrologia E Urologia Vera Cruz Ltda | composição farmacêutica carreadora de substáncias ativas |
CN115607738B (zh) * | 2022-10-31 | 2023-07-14 | 中国人民解放军陆军军医大学 | 基于仿生内皮细胞抗血栓功能的心血管植入物及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4951386A (ja) * | 1972-06-06 | 1974-05-18 | ||
JPS5664788A (en) * | 1979-10-27 | 1981-06-02 | Unitika Ltd | Method for imparting enzyme activity to solid surface |
JPS59204601A (ja) * | 1983-05-09 | 1984-11-20 | Unitika Ltd | 生理活性を有する成形体の製造方法 |
JPH05310868A (ja) * | 1992-05-11 | 1993-11-22 | Japan Synthetic Rubber Co Ltd | 医療材用組成物 |
JPH09503951A (ja) * | 1994-04-01 | 1997-04-22 | ミニメド インコーポレイテッド | 安定な酵素コーティングを備えた留置式カテーテル |
JPH10151189A (ja) * | 1996-07-29 | 1998-06-09 | Corvita Corp | 4級炭素を含むバイオ安定性エラストマー材料 |
JPH10328293A (ja) * | 1997-06-04 | 1998-12-15 | Unitika Ltd | 医療用具及びその製造方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4277560A (en) * | 1978-10-24 | 1981-07-07 | Technicon Instruments Corporation | Enzyme immunoassays using immobilized reagents in a flowing stream |
US4525456A (en) * | 1982-11-08 | 1985-06-25 | Uop Inc. | Support matrix and immobilized enzyme system |
GB2150833B (en) * | 1983-12-08 | 1987-04-15 | Ceskoslovenska Akademie Ved | Proteolytic wounds dressing |
US4757014A (en) * | 1985-11-08 | 1988-07-12 | Minnesota Mining And Manufacturing Company | Immobilization of biologically active protein on a polymeric fibrous support |
IL78826A (en) * | 1986-05-19 | 1991-05-12 | Yissum Res Dev Co | Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom |
US4885250A (en) * | 1987-03-02 | 1989-12-05 | E. I. Du Pont De Nemours And Company | Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports |
NO931809L (no) * | 1993-05-19 | 1994-11-21 | Norsk Hydro As | Hemofilter |
US6043099A (en) * | 1994-05-17 | 2000-03-28 | Spallholz; Julian E. | Method for the preparation of free radical pharmaceuticals, diagnostics and devices using selenium conjugates |
US5759836A (en) * | 1995-03-27 | 1998-06-02 | Hospital For Joint Diseases | Osteoarthritis-associated inducable isoform of nitric oxide synthetase |
US6033719A (en) * | 1996-04-25 | 2000-03-07 | Medtronic, Inc. | Method for covalent attachment of biomolecules to surfaces of medical devices |
US6177282B1 (en) * | 1997-08-12 | 2001-01-23 | Mcintyre John A. | Antigens embedded in thermoplastic |
AU8700798A (en) * | 1997-08-26 | 1999-03-16 | Technion Research & Development Foundation Ltd. | Intravascular apparatus and method |
US6024918A (en) * | 1998-03-13 | 2000-02-15 | Medtronic, Inc. | Method for attachment of biomolecules to surfaces of medical devices |
-
2002
- 2002-01-24 US US10/057,596 patent/US7407668B2/en active Active
-
2003
- 2003-01-23 JP JP2003561659A patent/JP2005532840A/ja not_active Ceased
- 2003-01-23 CA CA002478773A patent/CA2478773A1/en not_active Abandoned
- 2003-01-23 EP EP03732067A patent/EP1478412A2/en not_active Ceased
- 2003-01-23 WO PCT/US2003/002020 patent/WO2003061718A2/en active Application Filing
- 2003-01-23 AU AU2003210630A patent/AU2003210630A1/en not_active Abandoned
-
2008
- 2008-07-24 US US12/178,834 patent/US20080292678A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4951386A (ja) * | 1972-06-06 | 1974-05-18 | ||
JPS5664788A (en) * | 1979-10-27 | 1981-06-02 | Unitika Ltd | Method for imparting enzyme activity to solid surface |
JPS59204601A (ja) * | 1983-05-09 | 1984-11-20 | Unitika Ltd | 生理活性を有する成形体の製造方法 |
JPH05310868A (ja) * | 1992-05-11 | 1993-11-22 | Japan Synthetic Rubber Co Ltd | 医療材用組成物 |
JPH09503951A (ja) * | 1994-04-01 | 1997-04-22 | ミニメド インコーポレイテッド | 安定な酵素コーティングを備えた留置式カテーテル |
JPH10151189A (ja) * | 1996-07-29 | 1998-06-09 | Corvita Corp | 4級炭素を含むバイオ安定性エラストマー材料 |
JPH10328293A (ja) * | 1997-06-04 | 1998-12-15 | Unitika Ltd | 医療用具及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20030138415A1 (en) | 2003-07-24 |
US7407668B2 (en) | 2008-08-05 |
WO2003061718A3 (en) | 2003-12-04 |
CA2478773A1 (en) | 2003-07-31 |
WO2003061718A2 (en) | 2003-07-31 |
US20080292678A1 (en) | 2008-11-27 |
EP1478412A2 (en) | 2004-11-24 |
AU2003210630A1 (en) | 2003-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080292678A1 (en) | Medical articles having enzymatic surfaces for localized therapy | |
US9284409B2 (en) | Endoprosthesis having a non-fouling surface | |
US6599558B1 (en) | Treating metal surfaces to enhance bio-compatibility and/or physical characteristics | |
EP1051208B1 (en) | Hydrophilic coating for an intracorporeal medical device | |
ES2432388T3 (es) | Composiciones antiincrustantes, antimicrobianas y antitrombogénicas de injerto desde la superficie | |
US8894985B2 (en) | Nitric oxide-releasing polymers | |
JP3485264B2 (ja) | 生理活性物質が結合された生体適合性医療用金属材料及びその製造方法 | |
US6569688B2 (en) | Intravascular apparatus method | |
US20020009535A1 (en) | Superoxide dismutase or superoxide dismutase mimic coating for an intracorporeal medical device | |
JPH11505135A (ja) | 酸化窒素放出ニトロソ組成物およびそれらを再狭窄防止のために使用するためのデバイス | |
JP2007532197A (ja) | 生物活性物質のための被覆組成物 | |
WO2007058190A1 (ja) | 薬剤放出制御組成物および薬剤放出性医療器具 | |
CN105263536A (zh) | 活性剂在衬底上的固定 | |
JP2009518516A (ja) | 一酸化窒素放出ポリマー | |
JP2020501859A (ja) | 親水性ポリエーテルブロックアミドコポリマー表面からの疎水性活性薬の送達 | |
JP2002172159A (ja) | 体内埋め込み医療器具 | |
JP2007508912A (ja) | 溶出可能な表面コーティング | |
JP4261222B2 (ja) | 薬剤放出ステント | |
JP3776194B2 (ja) | 医療用具及びその製造方法 | |
JP2001000531A (ja) | 潤滑性を有する医療用具 | |
JP2004089233A (ja) | ステント | |
JP2004344469A (ja) | 体内埋込医療器具 | |
Amiji et al. | Albumin-modified biomaterial surfaces for reduced thrombogenicity | |
JP4460332B2 (ja) | ステント | |
JPH11299880A (ja) | カテーテル |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060120 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090305 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20090305 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090914 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100315 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110218 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20110218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110405 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110411 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20110617 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120426 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120507 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20130924 |